Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia
Clicks: 360
ID: 268032
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
65.3
/100
360 views
260 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #7 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract The goals of schizophrenia treatment are to control symptoms, prevent relapse, and improve functioning and quality of life. For many patients, these goals are not being met. This report highlights information provided by experts on the reasons for, impact of, and means to reduce relapse in patients with schizophrenia; on patient-centered and patient-reported assessment; […]
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (55 words).
Try re-searching for a better abstract.
| Reference Key |
correll2020theusing
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Christoph U. Correll;John Lauriello; |
| Journal | the journal of clinical psychiatry |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.